GEN Exclusives

More »

GEN News Highlights

More »
Apr 4, 2008

Deerfield Bankrolls Vivus’ Late-Stage ED Treatment with $30M

  • Deerfield Management will invest $30 million in Vivus to help the company further its erectile dysfunction drug avanafil. The treatment is a fast-acting, highly selective, phosphodiesterase type 5 inhibitor (PDE5i) and is in a Phase III study.

    Deerfield will provide $20 million under a royalty and funding agreement in the first 18 months. Deerfield will receive a royalty on sales of Muse, Vivus' marketed ED treatment, and avanafil if approved. Deerfield will also tender $10 million from the sale of Vivus’ common stock.

    “The market for ED therapies continues to grow. In 2007, sales of all PDE5i’s exceeded $3 billion, an increase of 15% over the previous year,” according to Leland Wilson, president and CEO of Vivus.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Lab-Grown Vaginas

Which body part do you think will be successfully engineered in the lab next?